Trials / Withdrawn
WithdrawnNCT02588625
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020. The purpose of Part B is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using two different doses of BMS-986020.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986020 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-10-01
- Completion
- 2019-10-01
- First posted
- 2015-10-28
- Last updated
- 2016-07-22
Locations
27 sites across 4 countries: United States, Canada, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT02588625. Inclusion in this directory is not an endorsement.